Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment

References

• Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 47(3):2010;243–248.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 363(20):2010;1889–1899.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 371(9610):2008;395–403.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355(16):2006;1672–1681.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357(22):2007;2237–2247.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118(1):2011;28–36.
   PubMed Web of Science ®Google Scholar
• Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 100(10):2002;3495–3503.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 114(18):2009;3748–3756.
   PubMed Web of Science ®Google Scholar
• Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 117(6):2002;844–850.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Junker P, Hasselbalch HC, Boiocchi L, Geyer JT, Feng X, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 155(2):2011;248–255.
   PubMed Web of Science ®Google Scholar
• Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol 25(1):2012;65–74.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Geyer JT, Lee CS, Boiocchi L, Imahiyerobo AA, Orazi A, et al. Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: A single center long-term follow-up. Haematologica 99(5):2014;937–44.
   Web of Science ®Google Scholar
• Ghanima W, Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol 47(3):2010;258–265.
   PubMed Web of Science ®Google Scholar
• Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol 15(20):2009;2433–2440.
   PubMed Web of Science ®Google Scholar
• Ting KR, Brady JJ, Hameed A, Le G, Meiller J, Verburgh E, et al. Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol 173(1):2016;82–8.
   PubMed Web of Science ®Google Scholar
• Horslev-Petersen K, Bentsen KD, Engstrom-Laurent A, Junker P, Halberg P, Lorenzen I. Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: Relation to clinical and serological parameters of inflammation during 8 and 24 months’ treatment with levamisole, penicillamine, or azathioprine. Ann Rheum Dis 47(2):1988;116–126.
   PubMed Web of Science ®Google Scholar
• Haukipuro K, Risteli L, Kairaluoma MI, Risteli J. Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings. Surgery 107(4):1990;381–388.
   PubMed Web of Science ®Google Scholar
• Bauermeister DE. Quantitation of bone marrow reticulin–a normal range. Am J Clin Pathol 56(1):1971;24–31.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van Der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):2005;1128–1132.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 139(3):2007;351–362.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Gminski DM, Rosenberg RD. Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. Blood 79(3):1992;619–626.
   PubMed Web of Science ®Google Scholar
• Rameshwar P, Chang VT, Thacker UF, Gascon P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis–pathophysiological implications. Am J Hematol 59(2):1998;133–142.
   PubMed Web of Science ®Google Scholar
• Papadantonakis N, Matsuura S, Ravid K. Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection. Blood 120(9):2012;1774–1781.
   PubMed Web of Science ®Google Scholar
• Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 123(5):2013;1887–1901.
   PubMed Web of Science ®Google Scholar
• Reilly JT, Brindley L, Kay M, Fielding S, Kennedy A, Dolan G, et al. Bone marrow and serum connective tissue polypeptides in idiopathic myelofibrosis. Clin Lab Haematol 17(1):1995;35–39.
   PubMedGoogle Scholar
• Laurent TC, Fraser JR. Hyaluronan, FASEB J Off Publ Fed Am Soc Exp Biol. 6(7):1992;2397–2404.
   Google Scholar
• Petrey AC, De La Motte CA. Hyaluronan, a crucial regulator of inflammation. Front Immunol 5:2014;101.
   PubMed Web of Science ®Google Scholar
• Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. Jl Bone Mineral Res 18(5):2003;859–867.
   PubMed Web of Science ®Google Scholar
• Hasselbalch H, Junker P, Lisse I, Lindqvist U, Engstrom Laurent A. Circulating hyaluronan in the myelofibrosis/osteomyelosclerosis syndrome and other myeloproliferative disorders. Am J Hematol 36(1):1991;1–8.
   PubMed Web of Science ®Google Scholar
• Hasselbalch H, Junker P, Lisse I, Bentsen KD. Serum procollagen III peptide in chronic myeloproliferative disorders. Scand J Haematol 35(5):1985;550–557.
   PubMedGoogle Scholar
• Brynes RK, Orazi A, Theodore D, Burgess P, Bailey CK, Thein MM, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study. Am J Hematol 90(7):2015;598–601.
   PubMed Web of Science ®Google Scholar
• Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol 95(7):2016;1077–1087.
   PubMed Web of Science ®Google Scholar
• Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, et al. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Am J Hematol 89(12):2014;E228–34.
   PubMed Web of Science ®Google Scholar
• Iraqi M, Perdomo J, Yan F, Choi PY, Chong BH. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica 100(5):2015;623–632.
   PubMed Web of Science ®Google Scholar
• Yanagida M, Ide Y, Imai A, Toriyama M, Aoki T, Harada K, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 99(4):1997;739–745.
   PubMed Web of Science ®Google Scholar
• Fujita S, Nakanishi T, Yoshimura H, Hotta M, Nakamichi N, Tamaki T, et al. TGFbeta(1) and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP. Thromb Res 130(3):2012;415–419.
   PubMed Web of Science ®Google Scholar
• Guo C, Chu X, Shi Y, He W, Li L, Wang L, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 27(6):2007;557–562.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Matsuoka H, Ochiai T, Matsushita R, Kubuki Y, Suzuki M, et al. Hepatocyte growth factor/scatter factor enhances the thrombopoietin mRNA expression in rat hepatocytes and cirrhotic rat livers. J Gastroenterol Hepatol 15(1):2000;83–90.
   PubMed Web of Science ®Google Scholar
• Kosone T, Takagi H, Horiguchi N, Toyoda M, Sohara N, Kakizaki S, et al. Hepatocyte growth factor accelerates thrombopoiesis in transgenic mice. Lab Invest 87(3):2007;284–291.
   PubMed Web of Science ®Google Scholar
• Feng X, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 96(4):2011;602–606.
   PubMed Web of Science ®Google Scholar